结核病检测市场：规模、占有率、监管、报销及 2036 年细分市场预测

结核病是由一组称为结核分枝桿菌复合群的细菌引起的细菌感染。结核病感染有不同的类型。原发性结核病可能没有症状，除非皮肤测试呈阳性，否则可能无法检测到。原发性结核病受到宿主的免疫反应的限制，导致无临床症状的潜伏感染。潜伏感染很少会发展为活跃感染。活动性结核病患者可出现咳嗽、体重减轻、盗汗、低烧、呼吸困难、淋巴结肿大、胸痛，甚至肺炎或气喘。潜伏性结核病是指患者体内处于潜伏状态的结核感染。对于高风险患者，感染可能会再次发生，因此在考虑治疗之前需要进一步的诊断测试。

结核病检测是透过分析痰液样整体发现活动性结核病和潜伏性结核病的。传统上，结核分枝桿菌感染的诊断依赖于痰液样本的阳性抹片、培养和胸部X光检查。为了快速诊断，可以进行核酸扩增测试，例如聚合酶链反应（PCR）、基于免疫的检测，例如酶联免疫吸附试验（ELISA）、皮肤斑贴试验和快速培养系统。

本报告对全球结核病检测市场进行了详细分析，包括竞争格局、 SWOT 分析、2036 年的市场预测、区域和国家趋势。

目录

目前可用的结核病检测和竞争格局

• 洞察关键产业趋势
• 2015 年至 2036 年结核病检测各细分市场总收入及市场预测
• 有关销售量、平均售价和市场价值的详细数据

全球、区域与国家洞察

• 结核病检测市场的 SWOT 分析
• 深入瞭解结核病检测市场的竞争动态与趋势
• 各国卫生系统概览
• 特定国家的报销政策
• 各国医疗科技法规

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Mycobacterium tuberculosis is a bacterial infection that can be caused by group of Mycobacterial species referred to as Mycobacterium tuberculosis complex. Tuberculosis infection can be of many different types. Primary tuberculosis may be asymptomatic and may only be recognized by a positive skin test. The primary tuberculosis can be limited by the host immune response leading to latent infection without clinical symptoms. The infection develops into active infection in few cases. Patients with active tuberculosis present with coughing, weight loss, night sweats, low-grade fever, dyspnea, lymphadenopathy, chest pain, and even pneumonia or phthisis. Latent Mycobacterium tuberculosis is a Mycobacterial infection that lies dormant in the patient. The infection can reactivate in high-risk patients and warrant an additional test for diagnosis to consider initiating treatment.

Mycobacterium tuberculosis tests are carried out to detect both active and latent forms of tuberculosis, through analysis of sputum samples. Traditional diagnosis of Mycobacterial infections depends upon smear positivity in sputum samples, culture and chest radiography. For rapid diagnosis, nucleic acid amplification tests such as polymerase chain reaction (PCR), immune-based assays such as enzyme-linked immunosorbent assay (ELISA), skin patch test and rapid culture systems are performed.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Mycobacterium Tuberculosis Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Mycobacterium Tuberculosis Tests market revenue by segment and market outlooks from 2015-2036.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Mycobacterium Tuberculosis Tests market.
• Competitive dynamics insights and trends provided for Mycobacterium Tuberculosis Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Companies covered: Qiagen NV, Oxford Immunotec Ltd, Cepheid Inc, Molbio Diagnostics Pvt Ltd, Gen-Probe Inc., Roche Diagnostics International Ltd and others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Mycobacterium Tuberculosis Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving Mycobacterium Tuberculosis Tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Mycobacterium Tuberculosis Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Mycobacterium Tuberculosis Tests market from 2015-2036.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.